X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a report published on Friday morning, Benzinga reports. They currently have a $5.00 price objective on the stock.

Separately, Cantor Fitzgerald reiterated an overweight rating and set a $5.00 price objective on shares of X4 Pharmaceuticals in a research note on Friday, May 31st.

X4 Pharmaceuticals Trading Down 13.4 %

NASDAQ:XFOR opened at $0.58 on Friday. X4 Pharmaceuticals has a one year low of $0.57 and a one year high of $2.06. The company has a debt-to-equity ratio of 52.92, a quick ratio of 3.71 and a current ratio of 3.71. The firm has a market cap of $97.41 million, a P/E ratio of -0.83 and a beta of 0.40. The firm has a 50-day simple moving average of $1.02 and a 200-day simple moving average of $0.99.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Equities analysts anticipate that X4 Pharmaceuticals will post -0.55 EPS for the current fiscal year.

Institutional Trading of X4 Pharmaceuticals

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC grew its position in X4 Pharmaceuticals by 38.8% during the 4th quarter. SG Americas Securities LLC now owns 47,668 shares of the company’s stock worth $40,000 after purchasing an additional 13,328 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of X4 Pharmaceuticals by 46.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock valued at $55,000 after acquiring an additional 12,514 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at $678,000. Kingdon Capital Management L.L.C. lifted its stake in shares of X4 Pharmaceuticals by 76.0% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock valued at $2,913,000 after purchasing an additional 1,500,000 shares during the period. Finally, Bain Capital Life Sciences Investors LLC lifted its stake in shares of X4 Pharmaceuticals by 6.0% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock valued at $14,184,000 after purchasing an additional 955,196 shares during the period. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.